Abstract
Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.
Keywords: Pancreatic cancer, transforming growth factor beta, tumor microenvironment, immunosuppression, targeted therapies, trabedersen (AP 12009), small molecule inhibitors of TGF-βRI, tumor tissue, antisense compounds, pancreatic adenocarcinoma carries, epithelial cells, antitumoral immune response, growth factors, unique microenvironment harbors, chronic pancreatitis tissue
Current Pharmaceutical Biotechnology
Title: Transforming Growth Factor Beta in Pancreatic Cancer
Volume: 12 Issue: 12
Author(s): Andreas Hilbig and Helmut Oettle
Affiliation:
Keywords: Pancreatic cancer, transforming growth factor beta, tumor microenvironment, immunosuppression, targeted therapies, trabedersen (AP 12009), small molecule inhibitors of TGF-βRI, tumor tissue, antisense compounds, pancreatic adenocarcinoma carries, epithelial cells, antitumoral immune response, growth factors, unique microenvironment harbors, chronic pancreatitis tissue
Abstract: Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.
Export Options
About this article
Cite this article as:
Hilbig Andreas and Oettle Helmut, Transforming Growth Factor Beta in Pancreatic Cancer, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808356
DOI https://dx.doi.org/10.2174/138920111798808356 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analytical Approaches for Assaying Metallodrugs in Biological Samples: Recent Methodological Developments and Future Trends
Current Drug Metabolism Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Functions of S100 Proteins
Current Molecular Medicine Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels
Current Topics in Medicinal Chemistry Recent Progress in Polynuclear Ruthenium Complex-Based DNA Binders/Structural Probes and Anticancer Agents
Current Medicinal Chemistry Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription
Current Molecular Pharmacology Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
Current Pharmaceutical Design Recent Progress in Anticancer Agents Incorporating Pyrazole Scaffold
Mini-Reviews in Medicinal Chemistry Modulation of the Peripheral and Central Inflammatory Responses by a-Melanocyte Stimulating Hormone
Current Protein & Peptide Science Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets